Millipore Sigma Vibrant Logo

OP30L Anti-c-Myc (Ab-2) Mouse mAb (8)

Anti-c-Myc (Ab-2) Mouse mAb (8): Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
OP30L
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
—
Solicitar precio
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      Host
      M
      Description
      Overview

      This product has been discontinued.





      Recognizes the ~60-67 kDa c-Myc protein in HL60 cells.
      Catalogue NumberOP30L
      Brand Family Calbiochem®
      References
      ReferencesLeGouy, E., et al. 1987. In Nuclear Oncogenes, Cold Spring Harbor Laboratory, 144.
      Cole, M.D., 1986. Ann. Rev. Gen. 20, 361.
      Nisen, P.D., et al. 1986. Cancer Res. 46, 6217.
      Erisman, M.D., et al. 1985. Mol. Cell. Biol. 5, 1969.
      Nau, M.N., et al. 1985. Nature 318, 69.
      Persson, H., et al. 1984. Science 225, 687.
      Alitalo, K., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1707.
      Dalla-Favera, R., et al. 1983. Science 219, 963.
      Product Information
      FormLyophilized
      FormulationLyophilized from a volatile buffer, 1 mg/ml BSA.
      Negative controlHT1080 cells
      Positive controlHL-60 cells
      PreservativeNone
      Applications
      Key Applications Immunoblotting (Western Blotting)
      Immunoprecipitation
      Not Paraffin Sections
      Application NotesImmunoblotting (1-5 µg/ml)
      Immunoprecipitation (1-2 µg/sample)
      Paraffin Sections (not recommended)
      Application CommentsThe c-myc protein is extremely labile. c-myc can be degraded during a freeze/thaw cycle; thus, we recommend using fresh lysates with a cocktail of protease inhibitors. c-myc is often destroyed during the processing of paraffin sections and can therefore be difficult to detect in this application. The sequence of c-myc predicts a ~45 kDa protein, but c-myc migrates under reducing conditions as a ~64-67 kDa band. This is the preferred antibody for immunoblotting. For best results with immunoprecipitation, compare results with and without SDS. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenrecombinant, human c-myc
      ImmunogenHuman
      Clone8
      HostMouse
      IsotypeIgG2a
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsReconstitute the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage with 0.1% azide. Avoid freeze/thaw cycles of solutions.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      OP30L 0

      Documentation

      Anti-c-Myc (Ab-2) Mouse mAb (8) Certificados de análisis

      CargoNúmero de lote
      OP30L

      Referencias bibliográficas

      Visión general referencias
      LeGouy, E., et al. 1987. In Nuclear Oncogenes, Cold Spring Harbor Laboratory, 144.
      Cole, M.D., 1986. Ann. Rev. Gen. 20, 361.
      Nisen, P.D., et al. 1986. Cancer Res. 46, 6217.
      Erisman, M.D., et al. 1985. Mol. Cell. Biol. 5, 1969.
      Nau, M.N., et al. 1985. Nature 318, 69.
      Persson, H., et al. 1984. Science 225, 687.
      Alitalo, K., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1707.
      Dalla-Favera, R., et al. 1983. Science 219, 963.

      Folleto

      Cargo
      Caspases and other Apoptosis Related Tools Brochure
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision26-February-2008 JSW
      ApplicationImmunoblotting (1-5 µg/ml)
      Immunoprecipitation (1-2 µg/sample)
      Paraffin Sections (not recommended)
      DescriptionPurified mouse monoclnal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2 mouse myeloma cells. Recognizes the ~60-67 kDa (apparent MW) c-Myc protein.
      BackgroundThe v-myc oncogene, initially identified in the MC29 avian retrovirus, causes myelocytomas, carcinomas, sarcomas and lymphomas, and belongs to a family of oncogenes conserved throughout evolution. In humans the family consists of five genes: c-myc, N-myc, R-myc, L-myc and B-myc. In both mouse plasmacytomas and human Burkitt's lymphoma, coding sequences from the c-myc gene are translocated from their normal chromosomal position into a transcriptionally active immunoglobulin locus on another chromosome. Amplification of the c-myc gene has been found in several types of human tumors including lung, breast and colon carcinomas, while the N-myc gene has been found amplified in neuroblastomas, small cell lung carcinomas and Wilms tumors. L-myc is amplified in small cell lung cancer. Furthermore, elevated levels of myc mRNA and protein have been demonstrated in human tumors even in the absence of gene amplification. Immunological studies have shown that the human c-myc gene gives rise to at least two nuclear phosphoproteins of ~64 kDa and ~67 kDa that exhibit relatively short (30 min) half lives in vivo and exhibit DNA binding properties in vitro.
      HostMouse
      Immunogen speciesHuman
      Immunogenrecombinant, human c-myc
      Clone8
      IsotypeIgG2a
      Speciesavian, human, mouse
      Positive controlHL-60 cells
      Negative controlHT1080 cells
      FormLyophilized
      FormulationLyophilized from a volatile buffer, 1 mg/ml BSA.
      PreservativeNone
      CommentsThe c-myc protein is extremely labile. c-myc can be degraded during a freeze/thaw cycle; thus, we recommend using fresh lysates with a cocktail of protease inhibitors. c-myc is often destroyed during the processing of paraffin sections and can therefore be difficult to detect in this application. The sequence of c-myc predicts a ~45 kDa protein, but c-myc migrates under reducing conditions as a ~64-67 kDa band. This is the preferred antibody for immunoblotting. For best results with immunoprecipitation, compare results with and without SDS. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsReconstitute the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage with 0.1% azide. Avoid freeze/thaw cycles of solutions.
      Toxicity Standard Handling
      ReferencesLeGouy, E., et al. 1987. In Nuclear Oncogenes, Cold Spring Harbor Laboratory, 144.
      Cole, M.D., 1986. Ann. Rev. Gen. 20, 361.
      Nisen, P.D., et al. 1986. Cancer Res. 46, 6217.
      Erisman, M.D., et al. 1985. Mol. Cell. Biol. 5, 1969.
      Nau, M.N., et al. 1985. Nature 318, 69.
      Persson, H., et al. 1984. Science 225, 687.
      Alitalo, K., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 1707.
      Dalla-Favera, R., et al. 1983. Science 219, 963.